Memantine Hydrochloride Tablet
Product Images NDC 72162-2003

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 72162-2003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 01)

Chemical structure diagram of memantine hydrochloride, showing its bicyclic amine framework with attached methyl groups and the hydrochloride moiety. The structural formula highlights the arrangement of atoms within the active ingredient memantine hydrochloride.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 02)

A line graph displaying mean change from baseline in ADCS-ADL scores over 28 weeks of treatment. Two groups are shown: Placebo (black squares) and Memantine Hydrochloride (M.HCl, open circles). The graph illustrates trends in clinical improvement and decline with error bars representing SEM at each time point.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 03)

A line graph showing the cumulative percentage of patients on the y-axis plotted against ADCS-ADL change from baseline on the x-axis. Two data series are shown: one for Placebo (represented by squares) and one for Memantine Hydrochloride (M.HCl) (represented by circles). The graph compares the distribution of patient responses between the two groups.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 04)

A line graph showing mean (± SEM) change from baseline in SIB score over 28 weeks of treatment, comparing Placebo and Memantine Hydrochloride (M.HCl). The y-axis represents the mean change with clinical improvement above zero and clinical decline below zero. Data points show Placebo declining steadily and M.HCl remaining near baseline initially then declining less than Placebo over time.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 05)

A cumulative percentage graph showing patient data comparing placebo and Memantine Hydrochloride (M. HCl). The x-axis represents SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients. Data points for placebo are marked with squares, while Memantine Hydrochloride is marked with circles.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 06)

A line graph showing mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The vertical axis represents mean change with error bars, indicating clinical improvement or decline, and the horizontal axis indicates weeks of treatment from 0 to 24.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 07)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with lines denoted by squares and circles, respectively.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 08)

A line graph depicting mean change from baseline in SIB score over 24 weeks of treatment. Two groups are compared: placebo/donepezil (black squares) and memantine hydrochloride (M.HCl)/donepezil (white circles). The vertical axis represents the mean change with error bars, while the horizontal axis shows weeks of treatment. Clinical improvement and decline are indicated on the right.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 09)

A cumulative distribution graph comparing the change from baseline in SIB (Severe Impairment Battery) scores between two patient groups: one receiving Placebo/Donepezil and the other receiving Memantine Hydrochloride/Donepezil. The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Label (Lbl721622003)

Memantine Hydrochloride Tablets, USP 5 mg oral tablets in a container of 500 units. Label shows NDC 72162-2003-5 and states storage at 20° to 25°C, with a warning to keep out of reach of children. Relabeled by Bryant Ranch Prepack, Inc. and manufactured by Zydus Lifesciences Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.